Latest News and Press Releases

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day ...

The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to...

Austin, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Hematologic Malignancies Market Size Analysis: According to S&S Insider Research, the Hematologic Malignancies Market is projected to grow at 9.11%...

Initial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology...

Selbyville, Delaware, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Blood Cancer Diagnostics Market size was valued at approximately USD 12.4 billion in 2023 and is projected to grow at a CAGR of 6.8% between...

New York, United States , Sept. 06, 2024 (GLOBE NEWSWIRE) -- The Global Hematologic Malignancies Market Size is to Grow from USD 67.18 Billion in 2023 to USD 144.58 Billion by 2033, at a Compound...

WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight...

WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial...

Vancouver, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis...

Vancouver, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis...